Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 245 participants.
Also called NCT03060980
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 245 participants
- Sponsor
- Registry
-
NCT03060980
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Terminated
Technical summary
Registry record NCT03060980. Randomized; no masking; primary purpose treatment. Start 2017-03-03 (actual); primary completion 2018-01-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- ITCA 650 20/60 mcg/day
- Intervention (Drug)
- Empagliflozin (oral)
- Intervention (Drug)
- Glimepiride (oral)
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct03060980- Content hash
495e4212b88adf7d533fb12edac92723e1e3de2520da93c3642be1562eee3e64